Sports
Arthex Biotech Announces First Patient Dosed In Phase I-Iia Arthemirtm Trial For Myotonic Dystrophy Type 1 (DM1)
(MENAFN - PR Newswire) ARTHEx logo (PRNewsfoto/ARTHEx Biotech) -ATX-01 is the industry's first anti-microRNA therapeutic to be investigated in DM1 ...
By: menafn
- Oct 18 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS